Literature DB >> 17141359

Calciphylaxis: natural history, risk factor analysis, and outcome.

Roger H Weenig1, Lindsay D Sewell, Mark D P Davis, James T McCarthy, Mark R Pittelkow.   

Abstract

BACKGROUND: Calciphylaxis is characterized by ischemic cutaneous ulceration, high mortality, and ineffective treatment.
METHODS: We conducted a retrospective study of 64 patients with calciphylaxis (including 49 dialysis patients age- and sex-matched to 98 dialysis controls).
RESULTS: The estimated 1-year survival rate of calciphylaxis was 45.8%. Risk factors for calciphylaxis included obesity, liver disease, systemic corticosteroid use, calcium-phosphate product more than 70 mg(2)/dL(2), and serum aluminum greater than 25 ng/mL. Survival rates were similar for 16 patients who received parathyroidectomy and 47 who did not. An estimated 1-year survival rate of 61.6% was observed for 17 patients receiving surgical debridement compared with 27.4% for the 46 who did not (P = .008). LIMITATIONS: The study was limited by its retrospective design and there was no control group for the 15 nondialysis cases.
CONCLUSIONS: Calciphylaxis is multifactorial and usually fatal. Prevention of calciphylaxis may include correction of risk factors identified in this study. Surgical debridement was associated with improved survival, but parathyroidectomy was not.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17141359     DOI: 10.1016/j.jaad.2006.08.065

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  119 in total

1.  Clinical pearls in dermatology.

Authors:  Mark Denis P Davis; John B Bundrick; Scott C Litin
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

2.  Calciphylaxis: a review.

Authors:  Avani Bhambri; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2008-07

Review 3.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

4.  Case Report on Calciphylaxis: An Early Diagnosis and Treatment May Improve Outcome.

Authors:  Barbara J Marshall; Rachel E Johnson
Journal:  J Am Coll Clin Wound Spec       Date:  2013-11-12

5.  Warfarin-induced calciphylaxis.

Authors:  Muhsen Al-ani; Konstantinos Parperis
Journal:  BMJ Case Rep       Date:  2016-01-18

6.  Palliative Care Use and Patterns of End-of-Life Care in Hospitalized Patients With Calciphylaxis.

Authors:  Kabir O Olaniran; Shananssa G Percy; Sophia Zhao; Chantal Blais; Vicki Jackson; Mihir M Kamdar; Jeremy Goverman; Daniela Kroshinsky; Jennifer S Temel; Sagar U Nigwekar; Nwamaka D Eneanya
Journal:  J Pain Symptom Manage       Date:  2018-11-03       Impact factor: 3.612

Review 7.  Calciphylaxis: from the disease to the diseased.

Authors:  Tiago M Oliveira; João M Frazão
Journal:  J Nephrol       Date:  2015-04-03       Impact factor: 3.902

Review 8.  [Calciphylaxis. A call for interdisciplinary cooperation].

Authors:  V M Brandenburg; S Schmitz; J Floege; K Amann; M Ketteler
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

9.  Comparison of Safety Profiles of New Oral Anticoagulants with Warfarin Using the Japanese Spontaneous Reporting Database.

Authors:  Keiko Hosohata; Saki Oyama; Iku Niinomi; Tomohito Wakabayashi; Ayaka Inada; Kazunori Iwanaga
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

10.  First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification.

Authors:  J Perelló; P H Joubert; M D Ferrer; A Z Canals; S Sinha; C Salcedo
Journal:  Br J Clin Pharmacol       Date:  2018-10-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.